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 ABSTRACT 
OBJECTIVE:  The objective of this selective EBM review is to determine whether or not high 
dose radioactive iodine-131 is more effective than low dose iodine-131 in the therapy of patients 
with hyperthyroidism. 
STUDY DESIGN:  The review included three primary English language studies that were peer 
reviewed articles published in 2003, 2010 and 2011. 
DATA SOURCES:  This paper evaluates three randomized control trials (one prospective 
randomized and two comparative randomized) looking at the effectiveness of high dose and low 
dose radioactive iodine-131 for the treatment of hyperthyroidism.   
OUTCOMES MEASURED: Each study examined patients being treated with high or low dose 
radioactive iodine-131. The outcomes measured include 1) incidence of failed treatment that 
required further therapy 2) patients that maintained a euthyroid state 3) patients needing therapy 
for hypothyroidism caused by the radioactive therapy. The measurements were evaluated with 
laboratory values as well as a 5- point scoring system and clinical symptoms of hyperthyroidism 
and hypothyroidism. Statistical evaluation is based on p-values and NNT.  
RESULTS: Three randomized controlled trials were included in this review. Results from Leslie 
et al. 2003, found that low dose regimen is as effective as high dose regimen. The conclusion and 
statistical analysis of Pusuwan et al. 2011, found that high dose regimen would be more effective 
than low dose regimen. Lastly, the Thientunyakit et al. 2010, study found that neither dose 
regimen was shown to be more effective in the treatment of hyperthyroidism.   
CONCLUSION: All three of the randomized trials in this EBM review contradicted findings in 
the other.  That being said, at this time there is no conclusive evidence to support whether high or 
low dose radioactive iodine regimen is more effective in the treatment of hyperthyroidism. There 
has to be continued research and development in this field of study to better determine a dose 
regimen that is effective in managing patients with this disease.   
KEY WORDS: Iodine-131, Hyperthyroidism, Comparison, Treatment 
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INTRODUCTION 
Radioactive iodine was introduced as a means for treatment of hyperthyroidism in 1941 
by Hertz and Roberts in the United States.1 Radioactive iodine treatment has since been widely 
accepted as the gold standard for treatment of hyperthyroidism for over 50 years and is preferred 
over surgery or anti-thyroid medications.1 This form of therapy is primarily for patients that are 
in a hyperthyroid state and have medical complications associated with it or are symptomatic 
from this state. This form of treatment is relatively safe, simple and effective, but there still is a 
great deal of controversy surround the amount of radiation that the patient should receive to 
reach maximum efficacy. 2 The different theories for most effective dosing ranges from low dose 
verses high dose regimens. The dose regime is attained from calculated doses or fixed doses of 
iodine-131. With regards to low dose the treatment theory is to maintain a euthyroid state at least 
one year.1,2,3  High dose theory is to induce a state of hypothyroidism followed by hormone 
replacement maintenance. Calculations to determine the dose regimen takes into account gland 
size, presence of nodularity and results of a radioactive iodine uptake and scan.3 Another 
controversial theory is that of a fixed dose. This is when an institution uses a fixed dose method 
and treats everyone with the same dose no matter the severity of their hyperthyroidism. Another 
issue with deciding which method to use is that there is only about a 60% predictive rate for 
estimating euthyroidism in a patient receiving iodine-131 treatment.2,3 In the United States, the 
use of iodine-131 at a therapeutic level requires careful planning and patient education in regards 
to protecting the public from potentially harmful ionizing radiation that is released and excreted 
from the body.  
Hyperthyroidism is a disease state characterized by excessive production of thyroid 
hormones T3 and T4 by the thyroid which causes an increase in metabolic activity of the body.  
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It is estimated that about 3% of the world’s population is affected by hyperthyroidism.3 This can 
be measured with TSH and T3/T4 measurements and symptom profiles of patients.  
Hyperthyroidism can be broken up into primary, secondary and tertiary forms. The classification 
of the disease state is determined by the anatomical location of where the hyperthyroid state 
originates. It is estimated that about 60-80% of primary hyperthyroidism is associated with 
Graves’ disease.2 Hyperthyroidism may be associated with any age, sex and race. However, it is 
most common in women over the age of 60.1 Symptom profiles used to diagnose 
hyperthyroidism include fatigue, tremor, palpitations, diaphoresis, exophthalmos, increased 
appetite and weight loss. An increase of thyroid hormone can also exacerbate comorbidities 
especially cardiac in nature which can be fatal if left untreated.  
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not high dose 
radioactive iodine-131 is more effective than low dose iodine-131 in the therapy of patients with 
hyperthyroidism. 
METHODS  
Randomized control studies were selected on the basis of comparison of high verses low 
dose of radioactive iodine-131. The studies included subjects who presented with 
hyperthyroidism to the institution conducting the trial. The exclusion criteria included pregnant 
patients, patients that randomly converted to euthyroidism, patients lost to follow up, children 
less than 18 years old, patient refusal, physician refusal or patients previously treated with 
iodine-131.1,2,3 The outcomes measured in these studies included  persistent/recurrent 
hyperthyroidism, sustained euthyroidism and advancement to hypothyroidism.1,2,3 Treatment 
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success was considered sustained euthyroidism or induced hypothyroidism. Under these criteria, 
there were three randomized controlled comparative trials that were identified and included in 
this evidence based review.  
An extensive search utilizing PubMed and CINAHL was completed using the key words 
of “iodine-131”, “hyperthyroidism”, “comparison” and “treatment” to select relevant articles.  
All of the articles utilized in this review were published in peer reviewed journals and printed in 
English. The studies were also selected based on relevance and importance of the outcomes to 
the patient (POEMs). The included studies were RCTs that were published in 2003, 2010 and 
2011 with participants that were diagnosed with hyperthyroidism and underwent radioactive 
iodine-131 therapy. Exclusion criteria included: pregnancy, patients who randomly converted to 
euthyroidism, patients lost to follow up, children less than 18 years of age, patients that had a 
prior treatment with radioactive iodine-131 and patient or physician refusal. The summary of the 
statistical data was reported as p-values and NNTs.  
Table 1. Includes the demographics of the patients included in the RCTs. 
Study Type # 
Pts  
Age Inclusion Criteria Exclusion 
Criteria 
W/D Interventions 
Pusuwan et 
al. 
(2011) 
Prospective 
RCT 
145 41 +/- 
14 
years 
Patients referred to 
the Division of 
Nuclear Medicine 
Faculty of Medicine 
Siriraj Hospital who 
had not yet received 
radioactive iodine 
treatment-naïve 
patients.  
Patients 
younger than 
18 years old.  
Pregnancy or 
lactating 
patients.  
Previously 
treated with 
iodine-131 or 
surgery. 
Patients 
refusing 
treatment.  
Patients lost to 
follow up. 
5 High dose vs. 
Low dose 
iodine-131 
therapy.  
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Thientunyakit 
et al. 
(2010) 
Comparative 
evaluation 
RCT 
144 41 +/- 
14 
years 
All Hyperthyroid 
patients referred to 
the Nuclear 
Medicine 
Department, 
Songklanagarind 
University. 
Patients that 
had previously 
been treated 
with 
radioactive 
iodine. Eleven 
were excluded 
due to loss of 
follow up. Five 
became 
euthyroid 
before 
treatment.   
16 Calculated vs. 
Estimated 
high and low 
dose iodine-
131 therapy.  
Leslie et al. 
(2003) 
Prospective 
RCT 
88 41 +/- 
14 
years  
All patients being 
referred to the 
Nuclear Medicine 
Department at St. 
Boniface General 
Hospital for first 
treatment of Grave’s 
Disease 
hyperthyroidism. 
Patient 
preference for 
same day 
therapy.  
Patients from 
remote 
locations.  
Patient or 
physician 
refusal. 
Patients that 
were treated 
with iodine-
131 prior. 
0 Low-adjusted 
dose vs. High-
adjusted dose.  
 
OUTCOMES MEASURED  
 The outcomes measured were patient-oriented evidence that matters (POEMS).  To help 
measure subjective data, several clinical assessments were used to measure the outcome of the 
RCTs. Thientunyakit et al. 2010, managed this by evaluating a 5-point scoring system of clinical 
presentation for hyperthyroidism, symptomatic profile of fatigue, tremor, palpitations, 
diaphoresis, gland size or exophthalmos.3 Reversely a 5-point clinical scoring system for 
hypothyroidism post- treatment included swelling, bloating, constipation and cold sensation.3 
Hypothyroidism and hyperthyroidism symptoms were then correlated with biochemical 
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laboratory measurements of TSH and T3/T4. Leslie et al. 2003, evaluated physical exam and 
clinical symptoms most notably gland size and ophthalmopathy, and correlated symptomatology 
with biochemical laboratory examination. Pusuwan et al.2011, utilized a clinical evaluation of 
cardiac complications, glandular size and goiter, nausea and thyroiditis to monitor patients pre 
and post therapy.1 These clinical evaluations were also compared and correlated with 
biochemical TSH and T3/T4 levels.  
RESULTS 
Three comparative RCTs were evaluated with patients undergoing treatment with 
radioactive iodine -131. The comparative evaluation was based on high dose iodine and low dose 
iodine. All studies utilized similar processes with slight variations in each study. The three 
studies have similar inclusion and exclusion criteria (see Table 1 above). All studies used nuclear 
medicine departments and certified physicians to conduct the therapy process.1,2,3 This provided 
maximum safety and accuracy when calculating or estimating treatment doses. Follow up was 
conducted by trained personnel to ensure patient safety.  
Note that all of the studies that were evaluated contained dichotomous data. Statistical 
calculations used included numbers needed to treat (NNT) and p-values.  
The study performed by Leslie et al.2003, compared radioactive iodine-131 doses in the 
treatment of Graves’ Disease. Patients were first stratified based on their radioactive iodine 
uptake at four hours and were then randomized into one of four groups (high-fixed, low-fixed, 
high-adjusted and low-adjusted). Only high and low-adjusted dose arms of the study were 
examined in this review. A total of 43 patients were examined (low-adjusted, n=22; high 
adjusted n=21) and completed the study.2All of the patients in the stratified group received the 
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same therapy. The low-adjusted group received a dose of 2.96 MBq (megabequerel) (80 
µCi(microcurie))/g of thyroid tissue adjusted for 24-hour uptake percentage.2 The high-adjusted 
group received 4.44 MBq (120 µCi)/g of thyroid tissue adjusted for 24-hour uptake percentage.2 
Most patients received antithyroid medication before treatment. This medication was 
discontinued 5 days prior to therapy. Systemic beta-blockers were not discontinued during 
therapy for cardiac protection.2 Patients were then examined to evaluate if they failed therapy and 
remained hyperthyroid or if therapy was successful and they converted to hypothyroid or 
remained euthyroid.  Evaluation consisted of clinical evaluation of symptoms with physical 
exam and biochemical laboratory evaluation.2 The study also has a result of a NNT of 17.   
Table 2. Created from Leslie et al. 2003 Table 3.  
P-value= 0.05 Low-adjusted High-adjusted 
Hyperthyroid 4 (18%) 5 (24%) 
Euthyroid 0 (0%) 4 (19%) 
Hypothyroid 18 (82%) 12 (57%) 
Totals 22 (100%) 21 (100%)  
 
The study by Thientunyakit et al. 2010, was a comparative study of two different dosing 
protocols of radioactive iodine-131 in the treatment of hyperthyroidism. The study included 128 
patients; these patients were randomly placed in the separate arms of the study. One group 
contained 67 patients who received doses estimated by palpation alone, (100 µCi/ g of thyroid 
tissue for diffuse goiter and 200µ Ci/ g of thyroid tissue for nodular goiter).3 There was a 
maximum dose of 30 mCi (milicurie) set for these patients.3 The second arm of the study 
Warnecke, Hyperthyroidism: High vs. Low Dose Therapy, 7 
  
 
contained 61 patients and they were dosed with calculated method using palpation and 24-hour 
uptake percentage.3 In this study most patients received antithyroid medication before the 
therapeutic dose of iodine-131 was administered. These drugs were then discontinued at least 10 
days before the date of therapy.  Beta-blockers were not stopped for the therapy.  The patients 
were followed up to one year using a 5-point clinical symptom model as mentioned above and 
biochemical studies to correlate.3 The results at one year of induced hypothyroidism in estimated 
verses calculated were 48% to 52%, respectively.3 The results of persistent or recurrent 
hyperthyroidism were 55% vs. 45%, respectively.3 The results for euthyroidism were 52% vs. 
48%, respectively.3 With this data it can be observed a p-value of 0.185.  The NNT for this study 
was 10.  
Table 3. Key Statistical Values of the RCT being reviewed.  
 p-value CER EER RBI ABI NNT 
Leslie et al. 
(2003) 
0.05 18% 24% 86.7% 6% 17 patients  
Pusuwan et 
al. (2011) 
0.008 48% 30% 37.5% -18% -5 Patients 
Thientunyakit 
et al. (2010) 
0.185 45% 55% 22.2% 10% 10 patients  
CER= control adverse event, EER= experimental adverse event, RBI= relative benefit increase, ABI= 
Absolute benefit increase, NNT= numbers needed to treat. 
 
Pusuwan et al. 2011, conducted a prospective randomized study comparing the efficacy 
of high and low dose iodine-131 treatment for hyperthyroidism. This particular study took 150 
patients and randomly placed them into a high dose and low dose group.1 Any patients that were 
taking antithyroid medication were taken off of the medication 5-7 days prior to the therapy.  
The patient’s glad size was measured using a 24-hour uptake percentage.  A calculation was used 
with a formula of 150 µCi/g of thyroid tissue for the high dose arm and 100 µCi/ g of thyroid 
tissue.1 The study used the theory that failed therapy was maintained or recurrent 
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hyperthyroidism and successful treatment was defined as euthyroid state or hypothyroid state. 
Patients were followed one year by clinical symptomatology were specifically evaluated for 
nausea, heart failure and arrhythmias from increased metabolic activity and thyroiditis with 
biochemical evaluation via TSH and T3/T4.1 The success rate at one year was 70% for the high 
dose group and 52% for the low dose group with a p-value of 0.027.1 When doing statistical a 
statistical analysis on the trial it was found to have a p-value of 0.008.1 The NNT was calculated 
to be -5.  
DISCUSSION  
 There have been limited studies done on the effectiveness of high versus low does 
radioactive iodine-131 on patients with hyperthyroidism. Even though this has been the gold 
standard therapy for over 50 years1, many debate the differences in dose determination.  It is 
thought that this form of therapy is safe and effective but the most appropriate dose remains 
controversial when aiming to get a patient to a euthyroid state. However, maintaining 
euthyroidism maybe an ineffective goal in managing patients with iodine-131 because a large 
percentage of this population treated converts to hypothyroidism. The RCTs used considered 
iatrogenic hypothyroidism a successful treatment of hyperthyroidism, but for many practioners 
this is still argued as being unsuccessful. This is because hypothyroidism can be managed easily 
and the replacement hormone is fairly inexpensive. However, many patients do not want the 
burden of thyroid replacement hormone and periodic medicine management.  In Leslie et al. 
2003, and Thientunyakit et al. 2010, it was noted that the ability to predict the clinical outcome is 
only about 60% and shows the difficulty in the decision to pick high or low dose therapy for any 
given patient.2,3 In the trial done by Thientunyakit et al. 2010, the calculated dose and the 
estimated high and low dose groups had surprising similar outcomes and proved the low ability 
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to predict the clinical outcome of this procedure. The other studies carry clinically significant p-
values, showing if the patient would receive an adjusted low dose of radioactive iodine-131 they 
have an increased chance of failed therapy and subsequently would remain hyperthyroid. This 
would cause them to be clinically symptomatic following the 5-point scoring system and in need 
further treatment and subsequently more radiation, time and cost to the patient. Another aspect of 
clinical consideration is if you treat the patient and they in fact do become hypothyroid then they 
will require thyroid replacement hormone to avoid harmful hypothyroid sequela. These 
complications are also mentioned in the 5-point scoring system for hypothyroidism.  
 There are notable limitations in all three trials used in this review which demonstrate that 
more research needs to be done to better assess the dosing methods of iodine-131. For example 
all three trials had a low number of patients enrolled in the comparative studies.1,2,3 The ability to 
have a large number study is difficult because of the nature of the data being collected. There are 
theorized inherent risks of ionizing radiation; therefore, this limits the number of participants of 
this type of analysis. Each study reported that most patients were on antithyroid medication for a 
period of time before therapy. It is still unknown how much this can actually affect the uptake 
and efficacy of iodine-131 in the destruction of thyroid tissue. This could cause changes in 
patient preparation and outcome post-therapy. It is also mentioned that with different clinicians 
there could be a difference in estimated gland size when the thyroid is palpated. This can change 
dose amounts and cause outcome to vary as well. With these considerations in three RCTs 
reviewed, there needs to be many more studies in the evaluation of dose calculation and amount 
of iodine-131 that is used to treat hyperthyroidism.  
 As a final consideration, it is essential to follow patients with an iatrogenically induced 
hypothyroid state. There needs to be close follow up and management of these patients. It is 
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possible to have long term debilitation and sequela involved with hypothyroidism.3 Practioners 
need to be diligent and manage this condition closely so the patient can live a full life without 
comorbities caused by the iodine-131 therapy.  
CONCLUSION 
 After reviewing all three trials in this selective EBM review, the evidence is inconclusive 
and contradictory as to whether high or low dose radioactive iodine-131 is more effective in 
treatment of hyperthyroidism. Each study gives different outcomes and statistical data to whether 
high, low, adjusted or fixed doses are the best. The United States needs more research and 
development in this area of medicine to better understand the clinical outcomes it holds. This is 
evident with two of the studies being conducted in Thailand and the other being done in Canada. 
This information indicates the need for future research on the best way to dose patients to 
achieve positive outcome for the patient. The prognosis of patients with hyperthyroidism is good. 
However, ongoing research should be considered to identify a way to lengthen the time patients 
are in a euthyroid state. This will lower the chance of potentially harmful and unpleasant sequela 
from recurrent hyperthyroidism or induced hypothyroidism. This can also cut down the annual 
healthcare cost of retreatment courses, diagnostic tests, multiple office visits and thyroid 
replacement hormone therapy.
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